Explore the challenges and successes epilepsy centers face in implementing the newly expanded NAEC guidelines, particularly regarding mental health screenings and multidisciplinary care.
Explore the challenges and successes epilepsy centers face in implementing the newly expanded NAEC guidelines, particularly regarding mental health screenings and multidisciplinary care.
Discover how the new 2023 Guidelines for epilepsy centers highlight comprehensive care and the pivotal role of genetic testing in addressing health disparities and improving patient outcomes.
Discover how the new 2023 Guidelines for epilepsy centers highlight comprehensive care and the pivotal role of genetic testing in addressing health disparities and improving patient outcomes.
Dr Ivanhoe examines why she doesn't typically use oral medications for patients with spasticity, how to naviagate effective communication between clinician and patient, exciting new treatments on the horizon, and how not to lose "that human...
Dr Ivanhoe examines why she doesn't typically use oral medications for patients with spasticity, how to naviagate effective communication between clinician and patient, exciting new treatments on the horizon, and how not to lose "that human...
Dr Ivanhoe discusses everything from treatment variations between pediatric and adult patients to botulinum neurotoxin use and the nuanced factors influencing candidate selection to the profound impact of untreated spasticity on long-term...
Dr Ivanhoe discusses everything from treatment variations between pediatric and adult patients to botulinum neurotoxin use and the nuanced factors influencing candidate selection to the profound impact of untreated spasticity on long-term...
In Part 2 of this Q&A, Scott Otallah, MD, describes some of the challenges providers can expect to face when treating MS in pediatric patients as well as trends to keep an eye on in the near future.
In Part 2 of this Q&A, Scott Otallah, MD, describes some of the challenges providers can expect to face when treating MS in pediatric patients as well as trends to keep an eye on in the near future.
Treatment with the fully human monoclonal antibody apitegromab was associated with statistically significant improvements in motor function scores compared with placebo in patients with type 2 or type 3 spinal muscular atrophy (SMA).
Treatment with the fully human monoclonal antibody apitegromab was associated with statistically significant improvements in motor function scores compared with placebo in patients with type 2 or type 3 spinal muscular atrophy (SMA).
Older adults with chronic insomnia were 40% more likely to develop mild cognitive impairment or dementia over a median 5.6 years compared with older adults without insomnia, according to a study published in Neurology.
Older adults with chronic insomnia were 40% more likely to develop mild cognitive impairment or dementia over a median 5.6 years compared with older adults without insomnia, according to a study published in Neurology.
A novel physiological marker that quantifies the regulation dynamics of cerebral perfusion and oxygenation surpassed the performance of cognitive assessment tests and amyloid positron emission tomography (PET) in differentiating patients with...
A novel physiological marker that quantifies the regulation dynamics of cerebral perfusion and oxygenation surpassed the performance of cognitive assessment tests and amyloid positron emission tomography (PET) in differentiating patients with...
While regularity in day-to-day sleep patterns appears beneficial for cognitive function, sleep patterns that are rigid or highly regular may not be optimal in terms of serum brain-derived neurotrophic factor (BDNF).
While regularity in day-to-day sleep patterns appears beneficial for cognitive function, sleep patterns that are rigid or highly regular may not be optimal in terms of serum brain-derived neurotrophic factor (BDNF).
The US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for once-weekly subcutaneous lecanemab-irmb injections (LEQEMBI IQLIK) for the maintenance treatment of early Alzheimer disease (AD).
The US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for once-weekly subcutaneous lecanemab-irmb injections (LEQEMBI IQLIK) for the maintenance treatment of early Alzheimer disease (AD).
A history of moderate to severe traumatic brain injury (TBI) in US adult civilians was associated with an increased risk of developing a malignant brain tumor over follow-up.
A history of moderate to severe traumatic brain injury (TBI) in US adult civilians was associated with an increased risk of developing a malignant brain tumor over follow-up.
A patient-reported outcome tool developed by the American Academy of Sleep Medicine (AASM) is clinically valid, reliable, and feasible for monitoring treatment response and longitudinal symptom progression in adults with obstructive sleep...
A patient-reported outcome tool developed by the American Academy of Sleep Medicine (AASM) is clinically valid, reliable, and feasible for monitoring treatment response and longitudinal symptom progression in adults with obstructive sleep...
For those carrying the APOE4 gene, following a Mediterranean diet may lower the risk of developing Alzheimer disease and dementia, suggest study results published in Nature Medicine.
For those carrying the APOE4 gene, following a Mediterranean diet may lower the risk of developing Alzheimer disease and dementia, suggest study results published in Nature Medicine.
A drug used in Europe for treating respiratory conditions was safe, well-tolerated, and demonstrated target engagement in patients with Parkinson disease dementia (PDD).
A drug used in Europe for treating respiratory conditions was safe, well-tolerated, and demonstrated target engagement in patients with Parkinson disease dementia (PDD).
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
